ARDX Jan 2026 5.000 call
| Previous close | 2.9600 |
| Open | 2.9600 |
| Bid | 2.4500 |
| Ask | 3.6000 |
| Strike | 5.00 |
| Expiry date | 2026-01-16 |
| Day's range | 2.9600 - 2.9600 |
| Contract range | N/A |
| Volume | |
| Open interest | 392 |
Simply Wall St.When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
GlobeNewswireArdelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-execut
- GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time
